

*Dermatology Reports*

**Successfully maintained complete remission of mycosis fungoides by umbilical cord blood transplantation: a case report and literature review**

Munenari Itoh,<sup>1,2</sup> Sayaka Oshima,<sup>3</sup> Hiroto Ishii,<sup>3</sup> Shingo Yano,<sup>3</sup> Akihiko Asahina,<sup>1</sup> Yoshimasa Nobeyama<sup>1</sup>

<sup>1</sup>Department of Dermatology, The Jikei University School of Medicine, Tokyo; <sup>2</sup>Dermatology Clinic Itoin, Shizuoka; <sup>3</sup>Division of Clinical Oncology and Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan

doi: 10.4081/dr.2025.10222

**SUPPLEMENTARY MATERIAL**

**Supplementary Table 1.** Literature review of reported cases of cutaneous T-cell lymphomas treated with UCBT.

Case	Age/Sex	Diagnosis	Stage	Pathological findings	Extra-skin lesions	Therapies before transplantation	Duration of disease until transplantation	Remission-induction therapies (result)	Ablative regimen	UCB unit	Complications	Outcome	Ref.
1	35/M	MF	stage IIB (T3N2M0B0)	CD3 <sup>+</sup> CD4 <sup>+</sup> CD8 <sup>-</sup> bcl2 <sup>+</sup> CD30 <sup>-</sup> CCR4 <sup>+</sup> MIB1:50%	lymphadenopathy	topical steroid, NB-UVB, bexarotene, mogamulizumab	8 yrs	CHOP (failed), BV-CHP (CR)	CY/TBI	2.16×10 <sup>7</sup> cells/kg (CD34 <sup>+</sup> : 1.3×10 <sup>5</sup> cells/kg)	PIR, aGVHD (II)	CR (3 yrs and 10 ms)	ours
2	26/F	MF	stage IV	not described	lymphadenopathy, bone marrow invasion	biweekly CHOP, low-dose chemotherapy, allo-HSCT with reduced-intensity conditioning	1 yrs and 2 ms	cladribine and etoposide (failed)	CY/TBI	2.29×10 <sup>7</sup> cells/kg	not described	CR by GVL after stopping immunosuppressive agents due to relapse of MF (23 ms)	6

3	50/M	MF	stage IVA2 (T3N3M0B0)	CD4 <sup>+</sup>	lymphadenopathy, pleural effusion	excision of tumors, topical steroid, PUVA, IFN $\gamma$	9 yrs	THP-COP, electron beam, ESHAP (failed)	reduced-intensity (CHASE, hyperCVA D, TBI)	not described	not described	dead: pneumonia due to engraftment failure (day 23)	7
4	24/F	MF	stage IIA (T2N1M0B0)	CD3 <sup>+</sup> CD4 <sup>+</sup>	lymphadenopathy	topical steroid, PUVA, IFN $\gamma$	7 yrs and 6 ms	THP-COP, electron beam (relapsed)	reduced-intensity (CHASE, hyperCVA D, TBI)	not described	skin eruption	dead: relapse of MF and cerebral hemorrhage due to anticoagulant-related side-effects 23 days after 2nd allo-HSCT	7
5	28/F	MF	stage IIA (T2N1M0B0)	not described	lymphadenopathy, lung metastasis	topical steroid, PUVA, electron beam, CHOP	not described	THP-COP (PR)	CY/TBI	3.71 $\times$ 10 <sup>7</sup> cells/kg	not described	dead: CMV ventriculoencephalitis after 2 times failed and 3rd UCBT	8
6	34/F	folliculotropic MF	stage IVB (T3N3M1B0)	CD3 <sup>+</sup> CD4 <sup>+</sup> CD7 <sup>-</sup> CD8 <sup>-</sup>	lymphadenopathy, pleural effusion, lung metastasis	not described	not described	EPOCH (failed)	CY/TBI (lung complications) reduced-intensity (fludarabine, melphalan, TBI)	2.32 $\times$ 10 <sup>7</sup> cells/kg (CD34 <sup>+</sup> : 0.7 $\times$ 10 <sup>5</sup> cells/kg)	aGVHD	dead: relapse of MF (18 ms)	9
7	48/F	MF	stage IV with large cell transformation	CD3 <sup>-</sup> CD4 <sup>+</sup> CD7 <sup>-</sup>	lymphadenopathy, lung metastasis	not described	10 yrs	CHOP, CHOP with etoposide, ICE (PR)	fludarabine, TBI, cytoxan	one unit	aGVHD	alive, but relapse of MF despite 100% donor chimerism in bone marrow	10
8	43/M	Ichthyosiform MF	stage IVB (T2N3M1B1)	CD3 <sup>+</sup> CD4 <sup>+</sup> CD8 <sup>+</sup> CD20 <sup>-</sup> (CD4/CD8 double positive)	lymphadenopathy, cardiac involvement	gemcitabine (cardiac dysfunction did not improve)	not described	not described	not described	not described	not described	alive, but no detailed description	11
9	16/M	PCAE-CTL	stage IV	CD2 <sup>+</sup> CD3 <sup>+</sup> CD4 <sup>-</sup> CD8 <sup>+</sup> CD5 <sup>+</sup> CD7 <sup>+</sup> CD30 <sup>-</sup> CD56 <sup>-</sup> TIA-1 <sup>+</sup> Granzyme B <sup>+</sup>	cerebral infiltration	methotrexate	not described	whole-brain irradiation, EPOCH (PR)	CY/TBI, cytarabine	CD34 <sup>+</sup> : 1.5 $\times$ 10 <sup>5</sup> cells/kg	HHV-6 encephalopathy	CR (1yrs)	12

MF, mycosis fungoides; UCB, umbilical cord blood; NB-UVB, narrowband-UVB; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisolone; BV-CHP, brentuximab-vedotin, cyclophosphamide, doxorubicin, and prednisolone; CR, complete remission; CY, cyclophosphamide; TBI, total body irradiation; PIR, pre-engraftment immune reaction; aGVHD, acute graft-versus-host disease; GVL, graft-versus-lymphoma; PUVA, psoralen-UVA; IFN $\gamma$ , interferon-gamma; THP-COP, doxorubicin hydrochloride, vincristine sulfate, cyclophosphamide, prednisolone sodium succinate; ESHAP, etoposide, methylprednisolone, high-dose cytarabine, and cisplatin; CHASE, cyclophosphamide, cytarabine, etoposide, dexamethasone; hyper-CVAD, cyclophosphamide, vincristine, doxorubicin, dexamethasone; PR, partial remission; CMV, Cytomegalovirus; EPOCH, etoposide, prednisolone, vincristine, cyclophosphamide, doxorubicin; ICE, ifosfamide, carboplatin, etoposide; PCAE-CTL, primary cutaneous CD8<sup>+</sup> aggressive epidermotropic cytotoxic T-cell lymphoma; HHV-6, Human herpesvirus 6.

## References

1. Mori T, Shiratori S, Suzumiya J, et al. Outcome of allogeneic hematopoietic stem cell transplantation for mycosis fungoides and Sézary syndrome. *Hematol Oncol* 2020;38:266-71.
2. de Masson A, Beylot-Barry M, Ram-Wolff C, et al. Allogeneic transplantation in advanced cutaneous T-cell lymphomas (CUTALLO): a propensity score matched controlled prospective study. *Lancet* 2023;401:1941-50.
3. Yano S, Yokoyama H, Yanada M, et al. Role of alternative donor allogeneic hematopoietic stem cell transplantation in patients with intermediate- or poor-risk acute myeloid leukemia in first complete remission. *Bone Marrow Transplant* 2019;54:2004-12.
4. Gupta AO, Wagner JE. Umbilical Cord Blood Transplants: Current Status and Evolving Therapies. *Front Pediatr* 2020;8:1-11.
5. Peffault de Latour R, Brunstein CG, Porcher R, et al. Similar Overall survival using sibling, unrelated donor, and cord blood grafts after reduced-intensity conditioning for older patients with acute myelogenous leukemia. *Biol Blood Marrow Transplant* [Internet] 2013;19:1355-60. Available from: <http://dx.doi.org/10.1016/j.bbmt.2013.06.006>
6. Fukushima T, Horio K, Matsuo E, et al. Successful cord blood transplantation for mycosis fungoides. *Int J Hematol* 2009;88:596-8.

7. Tsuji H, Wada T, Murakami M, et al. Two cases of mycosis fungoides treated by reduced-intensity cord blood transplantation. *J Dermatol* 2010;37:1040-5.
8. Matsukawa T, Goto H, Takahashi K, et al. A fatal case of cytomegalovirus ventriculoencephalitis in a mycosis fungoides patient who received multiple umbilical cord blood cell transplantations. *Int J Hematol* 2012;95:217-22.
9. Nakaike T, Kato K, Oku S, et al. Reduced-intensity conditioning followed by cord blood transplantation in a patient with refractory folliculotropic mycosis fungoides. *Int J Hematol* 2013;98:491-5.
10. Pawar R, Kasi Loknath Kumar A, Woodroof J, et al. Skin Recurrence of Transformed Mycosis Fungoides Postumbilical Cord Blood Transplant despite Complete Donor Chimerism. *Case Rep Hematol* 2014;2014:1-5.
11. Kaku Y, Otsuka A, Tanizaki H, et al. Dual CD4/CD8-positive ichthyosiform mycosis fungoides with lymph node, peripheral blood and cardiac involvement: A case report. *Acta Derm Venereol* 2016;96:564-5.
12. Ichikawa S, Fukuhara N, Hatta S, et al. Successful cord blood stem cell transplantation for primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma complicated with cerebral infiltration. *Intern Med* 2018;57:2051-5.
13. Clark RA, Watanabe R, Teague JE, et al. Skin effector memory T cells do not recirculate and provide immune protection in alemtuzumab-treated CTCL patients. *Sci Transl Med* 2012;4:1-10.
14. Fuji S, Inoue Y, Utsunomiya A, et al. Pretransplantation anti-CCR4 antibody mogamulizumab against adult T-cell leukemia/lymphoma is associated with significantly increased risks of severe and corticosteroid-refractory graft-versus-host disease, nonrelapse mortality, and overall mortality. *J Clin Oncol* 2016;34:3426-33.